Natural and Synthetic Phosphodiesterase Inhibitors in 2023: an Update on the Impact on Neurological and Psychiatric Conditions
-
Published:2023-10-04
Issue:
Volume:23
Page:
-
ISSN:1389-5575
-
Container-title:Mini-Reviews in Medicinal Chemistry
-
language:en
-
Short-container-title:MRMC
Author:
Bentham Science Publisher Bentham Science Publisher
Abstract
Abstract:
This Perspective provides an updated overview on the involvement of phosphodiesterase (PDE)
isoforms and of the corresponding inhibitors in neurological disorders, including dementia, Parkinson’s
disease, multiple sclerosis, neuropsychiatric conditions and cerebral ischemia. Particular
attention has been dedicated to natural and semi-synthetic compounds. Translation into the clinic
of preclinical results, toxicity profile and bioavailability represent the challenging aspects in the
development of PDE inhibitors. With the aim of providing the latest updates to the reader, the
2023 contributions in the field were considered for the preparation of this Perspective
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,Pharmacology,General Medicine